UK markets closed

IQVIA Holdings Inc. (0JDM.L)

LSE - LSE Delayed price. Currency in USD
Add to watchlist
245.00+8.06 (+3.40%)
At close: 4:39PM BST
Full screen
Previous close236.94
Open245.00
Bid0.00 x 0
Ask0.00 x 0
Day's range245.00 - 245.00
52-week range245.00 - 245.00
Volume2
Avg. volumeN/A
Market cap48.835B
Beta (5Y monthly)1.46
PE ratio (TTM)116.67
EPS (TTM)2.10
Earnings date20 Jul 2021 - 26 Jul 2021
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • Business Wire

    Q² Solutions Announces Significant Expansion of Laboratory Operations in Scotland, UK

    MORRISVILLE, N.C., Jun 14, 2021--Q2 Solutions, a leading global clinical trial laboratory services organization and a wholly owned subsidiary of IQVIA, has announced the expansion of its laboratory and operational capabilities at its Alba Campus in Livingston, Scotland. This expansion of central labs, genomics, flow cytometry, and translational science laboratory services will support new growth areas for biopharma and pharma clients around the world and drive better patient outcomes.

  • IQVIA Holdings (IQV) Stock Up 55.4% Over a Year: Here's Why
    Zacks

    IQVIA Holdings (IQV) Stock Up 55.4% Over a Year: Here's Why

    IQVIA Holdings (IQV) stock is riding on consecutive better-than-expected top- and bottom-line performances, and an encouraging yearly guidance.

  • Business Wire

    Q2 Solutions and Tasso Collaborate to Provide Unique Solutions for Patients to Accelerate Adoption of Decentralized Clinical Trials

    Q2 Solutions, a wholly-owned subsidiary of IQVIA and a leading clinical trial laboratory services organization, today announced a transformative collaboration with Tasso Inc., a pioneer in clinical-grade, at-home, patient-centered blood testing, to develop diagnostic tests used in decentralized (virtual) clinical trials. These new laboratory-developed tests will use Tasso’s devices, enabling patients to collect their own blood using a virtually painless process from anywhere at any time.